However, a series of tests said it was nothing to worry about. But the line got darker — and in three months, she was told she had melanoma, a serious form of skin cancer, underneath her nail. That ...

A 38-year-old woman was diagnosed with stage 4 terminal cancer just days before giving birth to her son. For Kelly Heather, the first sign of melanoma she noticed was an unusual change in her ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Kelly Heather, 38, first noticed a dark line on her fingernail, which turned out to be an aggressive melanoma ... cancer, the mom of four says, “I do wonder what would have happened if I got that one ...